Related Experiment Video
Updated: May 1, 2026

12:30
Use of a Recombinant Mosquito Densovirus As a Gene Delivery Vector for the Functional Analysis of Genes in Mosquito Larvae
Published on: October 6, 2017
6.3K
Development and application of dengue virus reverse genetic systems.
1School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK, andrew.davidson@bristol.ac.uk.
Methods in Molecular Biology (Clifton, N.J.)
|April 4, 2014
Summary
Dengue virus reverse genetics systems enable studying viral replication and pathogenesis. These systems also facilitate developing potential dengue vaccines and antiviral drug screening using replicons.
Area of Science:
- Virology
- Molecular Biology
- Infectious Diseases
Background:
- Dengue virus research is advanced by reverse genetics systems.
- These systems utilize full-length cDNA clones of the viral RNA genome.
- They allow for studying mutations, developing vaccines, and creating replicons.
Purpose of the Study:
- To describe the development of dengue virus reverse genetic systems.
- To outline protocols for viral genome manipulation and infectious virus recovery.
- To detail the production of replicon-containing cell lines for research.
Main Methods:
- Construction of full-length cDNA clones of the dengue virus genome.
- Introduction of specific mutations or gene deletions into cDNA clones.
- Recovery of infectious dengue virus or replicons from transfected cells.
- Development of cell lines supporting replicon replication.
Main Results:
- Established dengue virus reverse genetic systems.
- Demonstrated the ability to generate infectious viruses with modified genomes.
- Produced replication-competent viral subgenomes (replicons) lacking structural genes.
- Created cell lines for studying viral replication and antiviral screening.
Conclusions:
- Dengue virus reverse genetics is a powerful platform for research.
- These systems are crucial for understanding dengue virus replication and pathogenesis.
- They are instrumental in developing novel dengue vaccine candidates and antiviral therapies.

